LIVE Keynote presentation: Facilitating the development of individualized therapies

•  Defining the need for individualized therapies 
• Current constraints to the development of individualized therapies and potential solutions 
• Regulatory issues related to the development of individualized therapies

Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER), FDA